Merck reported strong Q2 earnings, surpassing expectations and raising full-year EPS guidance, driven by robust sales of key products like SINGULAIR and GARDASIL. Management's confident tone, upcoming product launches, and strategic cost controls signal positive momentum. While increased Vioxx legal reserves introduce some uncertainty, the overall strong performance and optimistic outlook are likely to positively influence the stock price in the short term.

[1]